Vascular endothelial growth factor and angiopoietin-2 play a major role in the pathogenesis of vascular leakage in cirrhotic rats

Gut

Volumn 58, Issue 2, 2009, Pages 285-292

  Melgar Lesmes, P ^a   Tugues, S ^a   Ros, J ^a   Fernandez Varo G ^a   Morales Ruiz, M ^a   Rodes J ^a   Jimenez W ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; CARBON; EVANS BLUE; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTICLE; ASCITES; BLOOD VESSEL PERMEABILITY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; KIDNEY; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MESENTERY; METHODOLOGY; NONHUMAN; PANCREAS; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMALL INTESTINE; SPLEEN; TECHNIQUE; WESTERN BLOTTING;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; CAPILLARY PERMEABILITY; CARBON; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; INDOLES; LIVER; LIVER CIRRHOSIS; MALE; MESENTERY; MICROVESSELS; PANCREAS; POVIDONE; PYRROLES; RATS; RATS, WISTAR; RNA, MESSENGER; STAINING AND LABELING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 58849114178     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.155028     Document Type: Article

References (34)

1. Arroyo V, Ginés P, Jiménez W, et al. Renal dysfunction in cirrhosis. In: Bircher J, Benhamou JP, Mclntyre N, et al, eds. Oxford textbook of clinical hepatology, 2nd edn. Oxford: Oxford Medical Publications, 1999: 733-61.
2. Laffi G, Foschi M, Masini E, et al. Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. Hepatology 1995;22:1666-73.
3. Navasa M, Folio A, Filella X, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998;27:1227-32.
4. Jiménez W, Ros J, Morales-Ruiz M, et al. Nitric oxide production and inducible nitric oxide synthase expression in peritoneal macrophages of cirrhotic patients. Hepatology 1999;30:670-6.
5. Cejudo-Martin P, Morales-Ruiz M, Ros J, et al. Hypoxia is an inducer of vasodilator agents in peritoneal macrophages of cirrhotic patients. Hepatology 2002;36:1172-9.
6. Perez-Ruiz M, Ros J, Morales-Ruiz M, et al. Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide. Hepatology 1999;29:1057-63.
7. Morales-Ruiz M, Tugues S, Cejudo-Martin P, et al. Ascites from cirrhotic patients induces angiogenesis through the phosphoinositide 3-kinase/Akt signaling pathway. J Hepatol 2005;43:85-91.
8. Hyatt RE, Smith JR. The mechanism of ascites, a physiologic appraisal. Am J Med 1954;16:434-8.
9. Levy M, Wexler MJ. Renal sodium retention and ascites formation in dogs with experimental cirrhosis but without portal hypertension or increased splanchnic vascular capacity. J Lab Clin Med 1978;91:520-36.
10. Weis S M, Cheresh DA. Pathophysiological consequences of VEGF-A induced vascular permeability. Nature 2005;437:497-504.
11. Yancopoulos GD, Davis S, Gale NW, et al. Vascular specific growth factors and blood vessel formation. Nature 2000;407:242-8.
12. Morales-Ruiz M, Jiménez W. Neovascularization, angiogenesis, and vascular remodeling in portal hypertension. In: Sanyal AJ, Shah VH, eds. Portal hypertension. Pathogenesis, evaluation and treatment. 1st edn. Totowa: Humana Press, 2005:99-112.
13. Roviezzo F, Tsigkos S, Kotanidou A, et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 2005;314:738-44.
14. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441;437-43.
15. Clària J, Jiménez W. Renal dysfunction and ascites in carbon-tetrachloride-induced cirrhosis in rats. In: Ginés P, Arroyo V, Rodes J, Schrier RW, eds. Ascites and renal dysfunction in liver disease. Pathogenesis diagnosis and treatment, 2nd edn. Maiden, MA: Blackwell Science, 2005: 215-26.
16. Rogers DF, Boschetto P, Barnes PJ. Plasma exudation. Correlation between Evans blue dye and radiolabeled albumin in guinea pig airways in vivo. J Pharmacol Methods 1989;21:309-15.
17. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995;55:360-8.
18. Lortie M, Sirois MG, Couture R, et al. Regional changes in the extravasation of albumin in the canine kidney: comparison of bradykinin and water diuresis. Microvasc Res 1994;48:282-94
19. Dvorak HF, Nagy JA, Dvorak JT, et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988;133:95-109.
20. Yuan Y, Granger HJ, Zawieja DC, et al. Flow modulates coronary venular permeability by a nitric oxide-related mechanism. Am J Physiol 1992;263:H641-6.
21. Bosch J, García-Pagan JC. The splanchnic circulation in cirrhosis. In: Ginés P, Arroyo V, Rodes J, Schrier RW, eds. Ascites and renal dysfunction in liver disease, 2nd edn. Maiden: Blackwell Publishing, 2005: 156-63.
22. Bosch J, García-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32:141-56.
23. Tugues S, Fernández-Varo G, Munoz-Luque J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007;46:1919-26.
24. Rappaport AM, MacPhee PJ, Fisher MM, et al. The scarring of the liver acini (cirrhosis). Tridimensional and microcirculatory considerations. Vinchows Arch A Pathol Anat Histopathol 1983;402:107-37
25. Fernandez M, Mejias M, Angermayr B, et al. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 2005;43:98-103.
26. Brissova M, Shostak A, Shiota M, et al. Pancreatic islet production of vascular endothelial growth factor-A is essential for islet vascularization, revascularization, and function. Diabetes 2006;55:2974-85.
27. Sarelius IH, Kuebel JM, Wang J, et al. Macromolecule permeability of in situ and excised rodent skeletal muscle arterioles and venules. Am J Physiol Heart circ Physiol 2006;290:H474-80.
28. Rosmorduc O, Wendum D, Corpechot C, et al. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Path 1999;155:1065-73.
29. Sanger DR, Galli SJ, Dvorak AM, et al. Tumors cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
30. Maisonpierra PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
31. Nosada M, Chang L, McLean G, et al. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21 Cip1 repression. Mol Cell Biol 2004;24:8813-22.
32. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995;108:2369-79.
33. Esser S, Wolburg K, Wolburg H, et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 1998;140:947-59.
34. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet- derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.